MaxCyte Signs Strategic
Platform License with Be Biopharma to Support the Development of
Engineered B Cell Medicines (BCMs)
Be Biopharma to use
MaxCyte's Flow Electroporation® technology and ExPERT™ platform
within its Engineered B Cell Medicines programs
Rockville, MD, April 2, 2024 - MaxCyte, Inc.,
(Nasdaq: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and
innovative bioprocessing applications and Be
Biopharma ("Be Bio"), a
company pioneering the development of Engineered B
Cell Medicines (BCMs) to dramatically improve the lives of patients
who are living with genetic diseases, cancer, and other serious
conditions, today announced
the signing of a strategic platform license (SPL)
to support the development of Be Bio's BCMs programs.
Under the terms of the agreement, Be
Bio obtains non-exclusive research, clinical and commercial rights
to use MaxCyte's Flow Electroporation® technology and ExPERT™
platform. In return, MaxCyte is entitled to receive annual
licensing fees and program-related revenue.
"We are thrilled to support Be
Bio's pioneering efforts in the creation of Engineered B Cell
Medicines (BCMs)," said Maher Masoud, President and CEO of MaxCyte.
"Our technology and expertise will empower them to unlock the
potential of human B cells to address the unmet medical needs of
patients with genetic diseases, cancer, and beyond. This new class
of therapies could be transformative, and we are excited to be part
of this journey."
MaxCyte's ExPERT™ instrument
portfolio is the next generation of leading, clinically-validated
electroporation technology for complex and scalable cell
engineering. By delivering high transfection efficiency, seamless
scalability and enhanced functionality, the ExPERT™ platform
delivers the high-end performance essential to enabling the next
wave of biological and cellular therapeutics. Be Bio is MaxCyte's
27th clinical/commercial partnership
overall, each of which generates pre-commercial milestone
revenue, the vast majority of which include sales-based
payments.
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been designed to support
the rapidly expanding cell therapy market and can be utilized
across the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology platform, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at
maxcyte.com and
follow us on X (formerly Twitter) and
LinkedIn.
About Be Biopharma
Be Biopharma ("Be Bio") is pioneering
Engineered B Cell Medicines (BCMs) to dramatically improve the
lives of patients who are living with Hemophilia B and other
genetic diseases, cancer, and other serious conditions. With
eyes locked on the patient, our team of
purpose-driven scientists, technologists, manufacturing experts and
business builders collaborate
to create a bold new class of cell therapies. Be
Bio was founded in October 2020 by B cell engineering pioneers
David Rawlings, M.D., and Richard James, Ph.D., from Seattle
Children's Research Institute. Be Bio is backed by ARCH Venture
Partners, Atlas Venture, RA Capital Management, Alta Partners,
Longwood Fund, Bristol Myers Squibb, Takeda Ventures, Seattle
Children's Research Institute
and others. Since our founding, Be Bio's investors
have committed over $180 million to enable the Company to
re-imagine medicine based on the power of B cell therapy. For more
information, please visit us at be.bio and our
LinkedIn
page.
MaxCyte Contacts:
US IR
Adviser
Gilmartin
Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media
Relations
Spectrum Seismic
Collaborative
Anya Bolshem
abolshem@spectrumscience.com
+1 732-284-1751
Nominated Adviser and Joint
Corporate Broker
Panmure Gordon
Emma Earl / Freddy
Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR
Adviser
ICR
Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
Be
Bio Contacts:
Investor Relations
ir@be.bio
Media:
media@be.bio